Myths over medicines consumption and prices in Norway reviewed by trade group LMI

25 March 2013

There are a number of myths about overconsumption of and high prices for medicines in Norway. However, they are usually quite far from the truth, says the country's pharmaceutical manufacturers association, LMI, in a 90-page booklet of pharmaceutical statistics released last week.

In 2011, Norway had the lowest consumption of medicines in the Nordic countries. It was well below the average. In Western Europe, only the UK has lower prices on patented medicines than Norway, and even that may prove to be a temporary situation. Over the past decade, prices for Norwegian medicines have fallen by an average of 2.4% annually, while the consumer price index has risen by 1.8% on average. The result is an average annual price reduction (adjusted for inflation) of just over 4%.

Whereas health budgets are expanding considerably, the share used on medicines is falling. In 2005, medicines accounted for only 7.6% of public health expenses. Four years later the figure was 6.4%, and it continues to fall.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical